Home » Pipeline
Pipeline
February 21, 2020
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Atreca | ATRC-101 | Select solid tumor cancers | phase 1 first patient dosed |
| AXIM Biotechnologies | cannabinoid-based chewing gum with dronabinol | chemotherapy-related symptoms | phase 1 completed |
| Applied Genetic Technologies | AGTC-501 | X-linked retinitis pigmentosa | phase 1/2 enrollment completed |
| Molecular Templates | TAK-169 | relapsed/refractory multiple myeloma | phase 1 dosing initiated |
| Cyclo Therapeutics | Trappsol Cyclo | Niemann-Pick disease Type C | phase 1/2 patient enrollment completed |
| Harbour BioMed | HBM9161 | autoimmune diseases | phase 1 completed |
| ImmunogenX | Latiglutenase (IMGX003) | celiac disease | phase 2b enrollment started |
| Aravive | AVB-500 | platinum-resistant recurrent ovarian cancer | phase 1b enrollment started for higher dosage |
| BioXcel Therapeutics | BXCL501 | agitation in schizophrenia | phase 2 trial initiated |
| RIBOMIC | RBM-007 | exudative age-related macular degeneration | phase 2 first patient injected |
| DelMar Pharmaceuticals | VAL-083 | newly diagnosed, MGMT-unmethylated glioblastoma multiforme | phase 2 final patient enrolled and dosed |
| Palatin Technologies | topical PL9643 | dry eye disease | phase 2 initiated, first patient enrolled |
| Compugen | COM701, in combination with nivolumab and BMS-986207 | advanced solid tumors | phase 1/2 plans for initiation |
| Dyve Biosciences | DYV-700 | acute gout | phase 2 initiated, first patient enrolled |
| VBL Therapeutics | VB-111 in combination with nivolumab | metastatic colorectal cancer | phase 2 initiated |
| SCYNEXIS | ibrexafungerp | vulvovaginal candidiasis | phase 3 enrollment completed |
| Isofol Medical | arfolitixorin | metastatic colorectal cancer | phase 3 first patient in Japan dosed |
| Alnylam Pharmaceuticals | vutrisiran | ATTR amyloidosis | phase 3 enrollment completed |
| Axsome Therapeutics | AXS-007 | migraines | phase 3 enrollment completed |
| Epizyme | TAZVERIK (tazemetostat) | follicular lymphoma | priority review granted by the FDA |
| Seattle Genetics Astellas Pharma |
PADCEV (enfortumab vedotin-ejfv) | advanced bladder cancer | Breakthrough Therapy designation awarded by the FDA |
| Cardiovalve | Transcatheter Tricuspid Valve Replacement System | tricuspid regurgitation | Breakthrough Therapy designation awarded by the FDA |
| Horizon Therapeutics | PROCYSBI (cysteamine bitartrate) | nephropathic cystinosis | new dosage form approved by the FDA |
| Agile Therapeutics | Twirla (levonorgestrel and ethinyl estradiol) transdermal system | female hormone deficiency | approved by the FDA |
| Baudax Bio | ANJESO (meloxicam injection) | management of moderate to severe pain | approved by the FDA |
| Bristol-Myers Squibb | Opdivo (nivolumab) | unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy | approved by the Japan Ministry of Health, Labor and Welfare |
